Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531.
BM U2 531, the 2-[2-Cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)-]-propane, the further development of BM 06 002 is able to compensate the immunosuppressive action of Cyclophosphamide and to increase the carcinostatic action of Cyclophosphamide. These properties are demonstrated 1. by a leucocytosis induced after application of BM 12 531 in rats 2. by a quick restauration of leucocyte depression induced by Cyclophosphamide in rats and dogs 3. by an increase of resistance against an infection (candida albicans) in mice 4. by an increase of antitumour effect of Cyclophosphamide against a DS-carcinosarcoma in rats.
D000818:Animals; D001388:Aziridines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001389:Azirines / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000276:immunology; D002296:Carcinosarcoma / Q000188:drug therapy; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D004285:Dogs; D004357:Drug Synergism; D005260:Female; D007109:Immunity / Q000187:drug effects; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007962:Leukocytes / Q000187:drug effects; D007964:Leukocytosis / Q000139:chemically induced; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy
D001388:Aziridines; D001389:Azirines; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide